Skip to main content
OpenTrials
Completed

NCT Number: NCT00842751

Oral T7 Oral Testosterone in Man

The purpose of this study is to test how the body absorbs and processes new forms of oral testosterone. Information gained during the study may help develop better forms of testosterone therapy in the future.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–50 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 2

Primary location

University of Washington

Seattle, Washington, 98195, United States

About this study

We will be using three drugs: The first, acyline, temporarily turns off the body's production of testosterone for about two weeks. Subjects will receive acyline as shots three times over a six-week drug administration period. During the time when the body's production of testosterone is turned off, we will give testosterone either by itself or with a medication called finasteride by mouth twice daily for one week to see how much is absorbed and present in the bloodstream after administration. Subjects will go through three one-week study drug exposure periods. During two of the three one-week study drug administration periods subjects will also take a second medication, finasteride, by mouth twice daily. On the last day of each one-week drug administration period, subjects will be admitted to the University of Washington General Clinical Research Center overnight for monitoring of your blood testosterone levels. There will be 3 overnight visits for this study. This study will allow us to determine the absorption of testosterone taken by mouth, and the relative impact of two different doses of oral finasteride on testosterone absorption.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Males between 18 and 50 years of age
  • In good health based on normal screening evaluation (consisting of a medical history, physical exam normal serum chemistry, hematology, and baseline hormone levels.
  • Must agree to not participate in another research drug study
  • Must agree to not donate blood
  • Must be willing to comply with the study protocol and procedures

Exclusion criteria

  • Men in poor general health, with abnormal blood results (clinical laboratory tests or hormone values)
  • A known history of alcohol or drug abuse
  • Participation in a long-term male contraceptive study within the past month
  • History of bleeding disorders or current use of anti-coagulants
  • History of sleep apnea
  • History of major psychiatric disorder
  • Body mass index > 37
  • Infertility
  • Hematocrit > 55 or < 30
  • PSA >4

Treatment and study plan

First Intervention (7 days)

Drug

Acyline 300mcg/kg subcutaneous (days 1, 15 & 29) + testosterone undecanoate 200 mg, twice daily orally + finasteride placebo

Other names: propecia

First Washout (7 days)

Other

Washout of 7 days between each of the 3 treatment arms

Other names: no active drugs

Second Intervention (7 days)

Drug

Acyline 300mcg/kg subcutaneous + testosterone undecanoate 200 mg, twice daily orally + finasteride 0.5mg twice daily, orally

Other names: propecia

Third Intervention (7 days)

Drug

Acyline 300mcg/kg subcutaneous + testosterone undecanoate 200 mg, twice daily orally + finasteride 1mg twice daily, orally

Other names: propecia

Second wash-out period

Other

Washout of 7 days between each of the 3 treatment arms

Other names: no active drug

Primary outcomes

  1. Maximum Testosterone Concentration

    Time frame: 0,1,2,4,8,and 12-hour post dose

    Area under the curve of serum testosterone Pharmacokinetic measures time-weighted mean concentration calculated as area under the concentration curve (AUC) divided by time from initiation of dosing for the morning dose and corrected for differences in baseline hormone concentration.

  2. Serum Dihydrotestosterone Concentration

    Time frame: 0,1,2,4,8,and 12-hour post dose

    Area under the curve of serum dihydrotestosterone

  3. Serum Estradiol Concentration

    Time frame: 0,1,2,4,8,and 12-hour post dose

    Area under the curve of serum estradiol

Sponsors and collaborators

Lead sponsor

University of Washington

Other

Collaborators

  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
  • National Institutes of Health (NIH)

Registry information

Official study title

Pharmacokinetics of a Novel Oral Testosterone Undecanoate Formulation With Concomitant Inhibition of 5alpha-Reductase by Finasteride

Acronym: Oral T7

Important dates

Study start
2009
Primary completion
2009
Study completion
2009
First posted
Feb 12, 2009
Registry last updated
Jan 13, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.